CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
NanoPac®drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03077685
NCT03077685Phase 2Completed
CompareCT.gov

Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma

NanOlogy, LLC·interventional·Posted Mar 13, 2017·Updated Jun 24, 2024

In Brief

A Phase 2 clinical trial evaluating NanoPac® for Locally Advanced Pancreatic Adenocarcinoma. Completed, enrolled 54 participants across 4 sites.

Detailed Summary

Open-label, dose-escalating, Phase IIa trial of NanoPac® to treat subjects with locally advanced pancreatic adenocarcinoma via direct intratumoral injection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocally Advanced Pancreatic Adenocarcinoma
CountriesUnited States
CollaboratorsUS Biotest, Inc.

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 13, 2017
Enrollment StartDec 1, 2017
Primary CompletionMar 15, 2023
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 9.3 years ago

Interventions

NanoPac®drug

Subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.